308 related articles for article (PubMed ID: 1631805)
1. K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.
Collen D; Nelles L; De Cock F; Lemmens G; Van Coetsem T; Demarsin E; Lijnen HR
Thromb Res; 1992 Feb; 65(3):421-38. PubMed ID: 1631805
[TBL] [Abstract][Full Text] [Related]
2. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
Vandamme AM; Dewerchin M; Lijnen HR; Bernar H; Bulens F; Nelles L; Collen D
Eur J Biochem; 1992 Apr; 205(1):139-46. PubMed ID: 1313361
[TBL] [Abstract][Full Text] [Related]
4. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
5. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator.
Gheysen D; Lijnen HR; Piérard L; de Foresta F; Demarsin E; Jacobs P; De Wilde M; Bollen A; Collen D
J Biol Chem; 1987 Aug; 262(24):11779-84. PubMed ID: 3114253
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
Nelles L; Lijnen HR; Collen D; Holmes WE
J Biol Chem; 1987 Aug; 262(22):10855-62. PubMed ID: 2956260
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
Jiao J; Yu M; Ru B
Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.
Holvoet P; Laroche Y; Stassen JM; Lijnen HR; Van Hoef B; De Cock F; Van Houtven A; Gansemans Y; Matthyssens G; Collen D
Blood; 1993 Feb; 81(3):696-703. PubMed ID: 8427962
[TBL] [Abstract][Full Text] [Related]
10. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
Lu HR; Lijnen HR; Stassen JM; Collen D
Blood; 1991 Jul; 78(1):125-31. PubMed ID: 1906351
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
J Biol Chem; 1988 Dec; 263(35):19083-91. PubMed ID: 3143723
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
[TBL] [Abstract][Full Text] [Related]
13. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator.
Lijnen HR; Piérard L; Reff ME; Gheysen D
Thromb Res; 1988 Dec; 52(5):431-41. PubMed ID: 3146822
[TBL] [Abstract][Full Text] [Related]
15. Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction.
Van de Werf F; Lijnen HR; Collen D
Coron Artery Dis; 1993 Oct; 4(10):929-33. PubMed ID: 8269200
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase.
Holvoet P; Laroche Y; Lijnen HR; Van Cauwenberge R; Demarsin E; Brouwers E; Matthyssens G; Collen D
J Biol Chem; 1991 Oct; 266(29):19717-24. PubMed ID: 1918077
[TBL] [Abstract][Full Text] [Related]
17. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
Collen D; Dewerchin M; Rapold HJ; Lijnen HR; Stassen JM
Circulation; 1990 Nov; 82(5):1744-53. PubMed ID: 2121385
[TBL] [Abstract][Full Text] [Related]
18. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
[TBL] [Abstract][Full Text] [Related]
19. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
20. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
Holvoet P; Laroche Y; Lijnen HR; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
Eur J Biochem; 1992 Dec; 210(3):945-52. PubMed ID: 1483477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]